rz-001
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 29, 2022 (NCT05595473)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Telomerase reverse transcriptaseMODULATOR
TERT modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06695026 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2024 | Rznomics, Inc. |
| NCT06102525 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Rznomics, Inc., Sungkyunkwan University, University of Ulsan |
| NCT05595473 | Phase 1/Phase 2 (Phase 2) | Jul 29, 2022 | Rznomics, Inc. |
| NCT06676891 | N/A | — | Rznomics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rznomics, Inc. | For profit | 4 | 4 | 2 | 2022 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1